HC Wainwright Has Strong Forecast for CARM FY2024 Earnings

Carisma Therapeutics, Inc. (NASDAQ:CARM) – Equities researchers at HC Wainwright upped their FY2024 EPS estimates for shares of Carisma Therapeutics in a note issued to investors on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.32) for the year, up from their prior forecast of ($1.33). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Carisma Therapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Carisma Therapeutics’ Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Trading Down 1.1 %

CARM stock opened at $0.84 on Wednesday. Carisma Therapeutics has a 12-month low of $0.80 and a 12-month high of $3.16. The business’s 50-day moving average is $0.96 and its 200 day moving average is $1.09. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock has a market cap of $35.11 million, a price-to-earnings ratio of -0.54 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CARM. Vanguard Group Inc. raised its position in Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after purchasing an additional 11,200 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics in the second quarter valued at $40,000. Wexford Capital LP raised its holdings in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Finally, Barclays PLC raised its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.